

# **Supplemental Material**

**Table S1. Adherence for the Review Cohort accounting for pre-enrollment.**

	Intervention (N=365)	Usual Care (N= 360)	Adjusted Odds Ratio (95% CI)
<b>Data completeness</b>			
Complete Pre and Post enrollment data	197 (54%)	227 (63%)	
Pre enrollment data only	36 (10%)	25 (7%)	
Post enrollment data only	56 (15%)	45 (13%)	
Missing both	76 (21%)	62 (17%)	
<b>Pre-Enrollment<sup>a, b</sup></b>			
	N=197	N=227	
Adherence, mean (95% CI)	65.8% (62.0, 69.5)	62.2 (58.6, 65.8)	
Adherence $\geq$ 80%, n (%)	83 (42%)	118 (52%)	1.31 (0.91, 1.90) <sup>d</sup>
<b>Post-Enrollment<sup>b, c</sup></b>			
	N=197	N=227	
Adherence, mean (95% CI)	72.0 (68.6, 75.4)	70.8 (67.6, 74.0)	
Adherence $\geq$ 80%, n (%)	112 (65%)	118 (55%)	1.75 (1.05, 2.93) <sup>e</sup>
Pre Adherence < 80%	60 (54%)	57 (48%)	
Pre Adherence $\geq$ 80%	52 (46%)	61 (52%)	

a – Adherence 12 months prior to registration to the study.


b -Patients were on warfarin prior to registration then adherence was calculated with TTR, if DOAC then adherence was calculated via PDC and if both then the average of TTR and PDC was used. Patient had to have at least 30 days of medication coverage to be evaluable.

c – Adherence 10 months post registration to the study.

d – Model adjusted by intervention arm and CHA<sub>2</sub>DS<sub>2</sub>-VASc score of < versus  $\geq$ 2 for men or < versus  $\geq$ 3 for women, with a random effect of clinic location.

e - Model adjusted by arm intervention, Pre-Enrollment adherence (<80% vs  $\geq$  80%), CHA<sub>2</sub>DS<sub>2</sub>-VASc score of < versus  $\geq$ 2 for men or < versus  $\geq$ 3 for women and the interaction of intervention arm and Pre-Enrollment adherence, with a random effect of clinic location.


**Figure S1. Alluvial plot demonstrating the evolution of anticoagulation fills and adherence by trial arm and subsequent primary adherence and secondary adherence.**



AC, Anticoagulation Choice (shared decision making), N/A, not applicable; Rx, prescription; UC, Usual Care.

*Primary adherence* reflects a prescription fill post the index visit, while *secondary adherence* reflects the PDC (for patients on a DOAC) and TTR (for patients on Warfarin). Patients fell in the N/A (not applicable) category if they did not have  $\geq 30$  days of coverage by medication fills or INR values. Patients fell in the N/A (not applicable) category for secondary adherence if they did not have  $\geq 30$  days of coverage by medication fills or INR values.

**Figure S2. Alluvial plot demonstrating the trial arm, start or review cohort assignment, pre-enrollment adherence, and subsequent primary adherence and secondary adherence.**




AC, Anticoagulation Choice (shared decision making); N/A, not applicable; Rx, prescription; UC, Usual Care

Cohort represents patients that are treatment naïve (start) or those that were on or were on an anticoagulant within 6 months prior to enrollment. Pre-enrollment adherence to anticoagulants does not apply to patients in the start cohort.

*Primary adherence* reflects a prescription fill post the index visit, while *secondary adherence* reflects the PDC (for patients on a DOAC) and TTR (for patients on Warfarin). Patients fell in the N/A (not applicable) category for secondary adherence if they did not have  $\geq 30$  days of coverage by medication fills or INR values.

**Figure S3. Alluvial plot demonstrating the trial arm, start or review cohort assignment, baseline risk level, pre-enrollment adherence, and subsequent primary adherence and secondary adherence.**



AC, Anticoagulation Choice (shared decision making); N/A, not applicable; Rx, prescription; UC, Usual Care.

Cohort represents patients that are either treatment naïve (start) or those who were on an anticoagulant within 6 months prior to enrollment. Pre-enrollment adherence to anticoagulants does not apply to patients in the start cohort.

The high-risk category represents patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$  for men or  $\geq 3$  for women.

*Primary adherence* reflects a prescription fill post the index visit, while *secondary adherence* reflects the PDC (for patients on a DOAC) and TTR (for patients on Warfarin). Patients fell in the N/A (not applicable) category for secondary adherence if they did not have  $\geq 30$  days of coverage by medication fills or INR values.